COVID-19 and the Rheumatologist: The Good, the Bad and the Ugly
Healio Rheuminations
English - January 08, 2021 12:00 - 21 minutes - 15.5 MB - ★★★★★ - 72 ratingsMedicine Health & Fitness arthritis autoimmune lupus medicine rheumatoid rheumatology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Infectious Endocarditis for the Rheumatologist, Part 3: The Immune System Behaving Badly
Next Episode: The Complement System for Dunces
We end the year with Leonard Calabrese, DO, giving us a summary of what we’ve learned about COVID-19 from the perspective of a rheumatologist.
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.
Intro :10 Calabrese introduction :24 In this episode :43 Nobody has complete control of the literature on COVID-19 1:39 What was ugly about COVID-19? 2:16 What was bad about COVID-19? 4:05 What good came from the COVID-19 pandemic? 7:07Brought to you by GSK. Consider the long-term impact of disease activity flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com.
The good things continued 10:20 JAK inhibitors 11:30 The best outcomes: Vaccines 14:15 Pertinent questions for the rheumatology community 16:45 Recap 20:12 Conclusion 21:41Disclosures: Calabrese reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr. Brown at [email protected]. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum